ASH President Comments on FDA Approval of First CART-Cell Therapy to Treat Childhood Leukemia

da Salute H24 — 30 agosto 2017 alle 19:21

Today the U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy for the treatment of children with relapsed/treatment-resistant CD-19 positive acute lymphocytic leukemia (ALL). Continua »


Scrivi un commento